The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum Meeting Abstract
| Authors: | Monk, B. J.; Grisham, R. N.; Marth, C.; Banerjee, S. N.; Hilpert, F.; Coleman, R. L.; Pujade-Lauraine, E.; Pignata, S.; Mirza, M. R.; Oza, A. M.; Del Campo, J. M.; Oehler, M. K.; James, A.; Christy-Bittel, J.; Barrett, E.; Boyd, A. P.; Vergote, I. |
| Abstract Title: | The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036904799 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.tps5610 |
| Notes: | Meeting Abstract: TPS5610 -- Source: Wos |
